Lab
Advanced Pain Management Specialists, LLC
Advanced Pain Management Specialists, LLC was paid $33.77M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 71% of everything it billed.
33Billing provider infoADVANCED PAIN MANAGEMENT SPECIALISTS, LLC
ANNAPOLIS, MD 21401
ANNAPOLIS, MD 21401
33aNPI1861418220assigned 07/15/2006
33bProvider typeClinical Medical Laboratory
28Total paid$33.77M
24GClaims494,543
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Maryland
Rank by total paid#2 of 93
Median peer was paid$430K
This provider vs. median79×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FREAS, DAMEAN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,989 | $1.33M | |
| 2019 | 31,402 | $1.43M | |
| 2020 | 100,265 | $5.02M | |
| 2021 | 84,627 | $5.32M | |
| 2022 | 91,782 | $6.47M | |
| 2023 | 99,130 | $7.65M | |
| 2024incomplete | 70,348 | $6.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 71% | 293,158 | 253,743 | $23.99M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 114,730 | 99,027 | $5.98M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.6% | 13,595 | 12,624 | $1.56M |
| 64483 | 1.6% | 7,935 | 6,396 | $547K | |
| 95886 | <1% | 2,172 | 1,912 | $162K | |
| 64484 | <1% | 3,454 | 2,815 | $135K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 1,358 | 968 | $130K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,784 | 820 | $130K |
| 95911 | <1% | 781 | 710 | $127K | |
| 64636 | <1% | 1,636 | 1,186 | $109K | |
| 64494 | <1% | 2,173 | 1,767 | $107K | |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | <1% | 127 | 125 | $106K |
85 more codes
| 20611 | <1% | 3,491 | $85K | |
| 64635 | <1% | 1,598 | $56K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12,582 | $53K |
| 62321 | <1% | 1,139 | $50K | |
| 64493 | <1% | 2,257 | $49K | |
| 62323 | <1% | 897 | $38K | |
| 27096 | <1% | 994 | $38K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 8,704 | $33K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,207 | $32K |
| 95910 | <1% | 178 | $25K | |
| 20553 | <1% | 1,367 | $20K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 2,510 | $19K |
| 72275 | <1% | 1,045 | $19K | |
| J7328 | Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | <1% | 476 | $19K |
| 99205 | Prolong outpt/office vis | <1% | 74 | $15K |
| 20610 | <1% | 2,311 | $13K | |
| 64495 | <1% | 356 | $12K | |
| 95913 | <1% | 42 | $10K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 113 | $9K |
| 95909 | <1% | 74 | $9K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 378 | $7K |
| 95885 | <1% | 126 | $7K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 185 | $6K |
| 77002 | <1% | 629 | $6K | |
| 20552 | <1% | 324 | $5K | |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 295 | $5K |
| 64491 | <1% | 84 | $5K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 504 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 254 | $4K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 115 | $3K |
| 64634 | <1% | 39 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 86 | $3K |
| 76942 | <1% | 39 | $2K | |
| 64633 | <1% | 35 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 235 | $1K |
| 64490 | <1% | 84 | $943.99 | |
| 80373 | <1% | 208 | $669.20 | |
| 80365 | <1% | 208 | $669.20 | |
| 96127 | <1% | 97 | $647.91 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 26 | $617.96 |
| 80346 | <1% | 208 | $607.47 | |
| 64454 | <1% | 17 | $511.05 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 13 | $463.36 |
| 80361 | <1% | 208 | $435.58 | |
| 80369 | <1% | 100 | $363.16 | |
| 64450 | <1% | 25 | $345.49 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 17 | $286.04 |
| 80368 | <1% | 141 | $284.00 | |
| 80355 | <1% | 141 | $284.00 | |
| 80366 | <1% | 141 | $281.00 | |
| 80320 | <1% | 100 | $222.48 | |
| 99443 | <1% | 15 | $210.00 | |
| 80305 | <1% | 73 | $171.20 | |
| 80354 | <1% | 50 | $154.00 | |
| 80348 | <1% | 50 | $154.00 | |
| 80372 | <1% | 50 | $154.00 | |
| 80353 | <1% | 50 | $119.70 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14 | $109.06 |
| 99441 | <1% | 19 | $2.51 | |
| 80349 | 0% | 14 | $0.00 | |
| 80357 | 0% | 14 | $0.00 | |
| 1101F | 0% | 50 | $0.00 | |
| 80359 | 0% | 14 | $0.00 | |
| 80324 | 0% | 14 | $0.00 | |
| 1036F | 0% | 54 | $0.00 | |
| 1006F | 0% | 71 | $0.00 | |
| 80345 | 0% | 14 | $0.00 | |
| 84311 | 0% | 14 | $0.00 | |
| 80367 | 0% | 14 | $0.00 | |
| 83986 | 0% | 14 | $0.00 | |
| 80358 | 0% | 14 | $0.00 | |
| 83789 | 0% | 14 | $0.00 | |
| 99442 | 0% | 30 | $0.00 | |
| 82542 | 0% | 14 | $0.00 | |
| 80356 | 0% | 14 | $0.00 | |
| G9365 | One high-risk medication ordered | 0% | 60 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 114 | $0.00 |
| 81002 | 0% | 14 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 51 | $0.00 |
| 82570 | 0% | 14 | $0.00 | |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 115 | $0.00 |
| 0518F | 0% | 59 | $0.00 | |
| 83992 | 0% | 14 | $0.00 | |
| 80360 | 0% | 14 | $0.00 | |
| 80362 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFREAS, DAMEAN (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.